Table 1.

Patient demographics and clinical characteristics for all patients ≤70 y of age at baseline

CharacteristicsNABTT historical: RT + non-TMZ drug (n = 217)EORTC phase III: RT + TMZ (n = 287)NABTT RT + TMZ: CD4 (n = 49)NABTT RT + TMZ + new agent (n = 244)
No. of patients (%)No. of patients (%)No. of patients (%)No. of patients (%)
Age
    Median (range), y54 (21-70)56 (19-70)58 (29-69)55 (21-70)
    50-70 y148 (68)197 (69)38 (78)162 (66)
Sex
    Male 140 (65)185 (64)28 (57)144 (59)
KPS*
    90-100129 (70)249 (86)39 (80)180 (77)
    60-8050 (30)38 (13)10 (20)64 (26)
Extent of surgery
    Biopsy26 (12)48 (17)9 (18)55 (23)
    Debulking 143 (66)239 (83)40 (82)186 (76)
    Other or missing*48* (22)3 (1)
Weeks from diagnosis to treatment
    Median (range)3.9 (1.0-9.7)5 (1.7-10.7)3.1 (2-7.7)4.1 (1.9-12.7)
MMSE score
    27-30138 (64)196 (68)117 (84)
    ≤2629 (13)81 (28)39 (16)
    Missing50 (23)10 (3)
Corticosteroids
    Yes147 (68)193 (67)42 (86)179 (73)
Histologic diagnosis
    Glioblastoma165 (98)221 (92)49 (100)239 (98)

Abbreviations: KPS, Karnofsky performance status; MMSE, minimental status examination.